ORGO(ORGO)
ORGO
ANALYST COVERAGE5 analysts
BUY
▲ +265.1%upside to target
PRICE
Prev Close
2.41
Open
2.38
Day Range2.38 – 2.49
2.38
2.49
52W Range2.04 – 7.08
2.04
7.08
8% of range
VOLUME & SIZE
Avg Volume
1.8M
FUNDAMENTALS
P/E Ratio
-20.5x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.38
Market-like
TECHNICAL
RSI (14)
29
Oversold
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 102 days
Aug 28
Key MetricsTTM
Market Cap$317.83M
Revenue TTM$513.57M
Net Income TTM-$284.0K
Free Cash Flow$17.08M
Gross Margin70.4%
Operating Margin2.1%
Net Margin-0.1%
Return on Equity-0.1%
Return on Assets-0.1%
Debt / Equity0.19
Current Ratio3.53
EPS TTM$-0.00
ORGO News
About
headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Website
Brian GrowChief Commercial Officer
David C. FranciscoChief Financial Officer
Gary S. GillheeneyPresident, Chief Executive Officer, Chair of the Board
Patrick BilboChief Operating Officer
Patrick McGuireChief Accounting Officer
Robert CavorsiChief Business Officer
William R. KolbSecretary
Lori H. FreedmanChief Administrative & Legal Officer